Many of these organs express GLP-1R, which gives GLP-1 analogue therapies the potential to alleviate the diabetic phenotype systemically and the potential to provide new treatments for other diseases such as dementia and CVD in non-diabetic individuals2,7. The gene discussed is GLP1R; the disease is dementia.